Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 12, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Global R&D, CSO | June 16, 2014 | June 18, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 16, 2014 · Filed June 18, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,017 |
Reported balance
After 2014-06-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2014-06-16 · Exercise / conversion · Acquired 7,500 · Balance 151,017 |
| Common StockSEC Table I · non-derivative | Direct | 146,614 |
Reported balance
After 2014-06-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2014-06-16 · Sale · Disposed 4,403 · Balance 146,614 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96). F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 145,114 |
Reported balance
After 2014-06-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2014-06-16 · Sale · Disposed 1,500 · Balance 145,114 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86). |
| Common StockSEC Table I · non-derivative | Direct | 143,517 |
Reported balance
After 2014-06-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2014-06-16 · Sale · Disposed 1,000 · Balance 143,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99). |
| Common StockSEC Table I · non-derivative | Direct | 144,517 |
Reported balance
After 2014-06-16 transaction · row 4
1 source rowRow 4 · 2014-06-16 · Sale · Disposed 597 · Balance 144,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.16 · Expires 2018-07-23 | Direct | 15,500 |
Reported balance
After 2014-06-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2014-06-16 · Exercise / conversion · Disposed 7,500 · Balance 15,500 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 4,770 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,770 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 5,568 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,568 |
| Common StockSEC Table I · non-derivative | IndirectCommon stock held in trust | 15,233 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 15,233 F7: Common stock held in grantor retained annuity trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96).
F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86).
F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95).
F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99).
F7: Common stock held in grantor retained annuity trust.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 12, 2026 19:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-26-002979 · tm262917-5_4seq1.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 19:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-24-070516 · tm2416928-3_4seq1.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 17:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001104659-23-075872 · tm2319786-4_4seq1.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| May 19, 2022 Filed May 23, 2022 18:49 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001104659-22-063972 · tm2216669-3_4seq1.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:33 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001104659-21-081587 · tm2119762-3_4seq1.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2031-06-11 F1 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 16:17 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001104659-20-065873 · a4.xml · derivative · entry 2 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 16:17 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001104659-20-065873 · a4.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 17:38 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 1,554 | $9.34 | $14,514.36 |
DisclosureSEC source: 0001104659-19-047308 · a4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,320 F1 · price: The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $9.09 to $9.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 16:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 6,646 | $8.83 | $58,684.18 |
DisclosureSEC source: 0001104659-19-047150 · a4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,766 F2 · price: The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.43 to $9.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the SEC, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:26 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 1,800 | $8.42 | $15,156.00 |
DisclosureSEC source: 0001104659-19-047150 · a4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,120 F1 · price: The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.29 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 23, 2019 Filed May 28, 2019 21:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 14,700 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001104659-19-032142 · a4.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 Underlying: Common Stock · 14,700 shares Expires 2029-05-23 F1 · derivative.exercise_date: The option will vest in full and become exercisable on the first anniversary of the grant date. Read SEC document |
| December 07, 2018 Filed Dec 7, 2018 17:50 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 6,905 | $5.01 | $34,594.05 |
DisclosureSEC source: 0001104659-18-071881 · a4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,320 Read SEC document |
| December 07, 2018 Filed Dec 7, 2018 17:50 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 495 | $5.00 | $2,475.00 |
DisclosureSEC source: 0001104659-18-071881 · a4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,415 Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 17:50 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 100 | $5.01 | $501.00 |
DisclosureSEC source: 0001104659-18-071881 · a4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,920 Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 17:50 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 1,295 | $5.00 | $6,475.00 |
DisclosureSEC source: 0001104659-18-071881 · a4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,820 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 17:34 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 2,062 | $5.15 | $10,619.30 |
DisclosureSEC source: 0001104659-18-071741 · a4.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,525 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 17:34 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 200 | $5.13 | $1,026.00 |
DisclosureSEC source: 0001104659-18-071741 · a4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,463 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 17:34 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 344 | $5.12 | $1,761.28 |
DisclosureSEC source: 0001104659-18-071741 · a4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,263 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 17:34 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 325 | $5.11 | $1,660.75 |
DisclosureSEC source: 0001104659-18-071741 · a4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,919 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 17:34 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | PurchaseCommon Stock | 1,076 | $5.09 | $5,476.84 |
DisclosureSEC source: 0001104659-18-071741 · a4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,594 Read SEC document |
| July 02, 2018 Filed Feb 14, 2020 16:25 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021807 · a4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 90,000 F2 · ownership.nature: Shares are held by the Peter Mueller 2018 Irrevocable Family Trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. Read SEC document |
| July 02, 2018 Filed Feb 14, 2020 16:25 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GiftCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021807 · a4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,795 F1 · balance_after: Number of shares held following the reported transaction reflects 41,475 shares of common stock that were inadvertently omitted from the reporting person's Form 3 filed on March 7, 2018. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 17:12 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Options · Derivative | 37,209 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001104659-18-017148 · a4.xml · derivative · entry 1 MUELLER PETER · CIK 0001256126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,397 Underlying: Common Stock · 37,209 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares underlying this stock option vest as follows: one-third (12,403 shares) on each of 3/12/2019, 3/12/2020 and 3/12/2021. Read SEC document |
| June 16, 2014 Filed Jun 18, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001209191-14-042313 · doc4.xml · derivative · entry 9 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 7,500 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| June 16, 2014 Filed Jun 18, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $70.29 | $70,290.00 |
DisclosureSEC source: 0001209191-14-042313 · doc4.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,517 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99). Read SEC document |
| June 16, 2014 Filed Jun 18, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 597 | $69.54 | $41,515.38 |
DisclosureSEC source: 0001209191-14-042313 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,517 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95). Read SEC document |
| June 16, 2014 Filed Jun 18, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $68.25 | $102,375.00 |
DisclosureSEC source: 0001209191-14-042313 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,114 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86). Read SEC document |
| June 16, 2014 Filed Jun 18, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,403 | $67.72 | $298,171.16 |
DisclosureSEC source: 0001209191-14-042313 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,614 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 16, 2014 Filed Jun 18, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $32.16 | $241,200.00 |
DisclosureSEC source: 0001209191-14-042313 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2014 Filed May 16, 2014 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001209191-14-034624 · doc4.xml · derivative · entry 8 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 7,500 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| May 14, 2014 Filed May 16, 2014 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $68.08 | $40,848.00 |
DisclosureSEC source: 0001209191-14-034624 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,517 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $68.08 (range $68.00 to $68.15). Read SEC document |
| May 14, 2014 Filed May 16, 2014 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,400 | $67.49 | $431,936.00 |
DisclosureSEC source: 0001209191-14-034624 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,117 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $67.49 (range $67.02 to $67.90). Read SEC document |
| May 14, 2014 Filed May 16, 2014 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $66.13 | $33,065.00 |
DisclosureSEC source: 0001209191-14-034624 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,517 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $66.13 (range $65.71 to $66.50). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2014 Filed May 16, 2014 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $32.16 | $241,200.00 |
DisclosureSEC source: 0001209191-14-034624 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (righty to buy) · Derivative | 5,750 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · derivative · entry 10 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 5,750 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · derivative · entry 9 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $63.27 | $44,289.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $63.27 (range $63.03 to $63.65). Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,800 | $62.38 | $112,284.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 5 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,450 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $62.38 (range $62.00 to $62.84). Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,900 | $61.53 | $178,437.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 4 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,250 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $61.53 (range $61.05 to $61.97). Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,100 | $60.57 | $127,197.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,150 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $60.57 (range $60.06 to $60.94). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,750 | $32.16 | $184,920.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2014 Filed Apr 17, 2014 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,750 | $28.84 | $50,470.00 |
DisclosureSEC source: 0001209191-14-028131 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 7,500 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,220 | $78.78 | $96,111.60 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $78.78 (range $78.50 to $79.36). Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,280 | $78.19 | $491,033.20 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,970 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $78.19 (range $77.50 to $78.49). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2014 Filed Mar 19, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $28.84 | $216,300.00 |
DisclosureSEC source: 0001209191-14-021850 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · derivative · entry 6 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 7,500 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 633 | $83.05 | $52,570.65 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · nonDerivative · entry 3 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,750 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $83.05 (range $82.96 to $83.18). Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,867 | $82.55 | $566,870.85 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · nonDerivative · entry 2 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,383 F1 · kind: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $82.55 (range $81.95 to $82.92). F3 · price: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 18, 2014 Filed Feb 20, 2014 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $28.84 | $216,300.00 |
DisclosureSEC source: 0001209191-14-012316 · doc4.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · EVP, Global R&D, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.